GENERIC NAME:
Empagliflozin

THERAPEUTIC SEGMENT:
Antidiabetic

INDICATIONS:

Sciampa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus as;

Monotherapy

When diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance.

Add-on combination therapy

In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycemic control.

BRIEF DESCRIPTION:
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Empagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Empagliflozin is also used in patients with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke.

DOSAGE FORM:
Tablet 10mg

Tablet 25mg

PACK SIZE:
Tablet 14's